Bionano Genomics Announces Participation at the European Society of Human Genetics Conference (ESHG) 2022 Featuring OGM Across a Broad Range of Clinical Research Applications and a Collaborative Product Development with Hamilton
June 10 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation at the European Society of Human Genetics (ESHG)
2022 Conference, with 13 scientific and poster presentations
highlighting the application of OGM across rare undiagnosed genetic
disease and genetic disorders. Additionally, Bionano and Hamilton
will present the Long String VANTAGE, the world’s first automation
solution for UHMW extraction used in OGM.
ESHG is an annual conference that brings together industry and
academic professionals to discuss new technologies and advances in
the field of human genetics. ESHG sessions will take
place June 11-14, 2022 virtually and in Vienna, Austria.
Bionano and Hamilton jointly announced the Long String VANTAGE,
which is the first Assay Ready Workstation solution in Hamilton´s
Long String Genomics product program which supports extraction of
UHMW DNA at increased scale. Attendees at ESHG will be able to
learn more about the Long String VANTAGE at both companies’ booths
and can experience a demonstration of the workflow at Hamilton’s
booth throughout the conference.
As part of a corporate satellite presentation, Dr. Detlef Trost
from Laboratoire CERBA, and Dr. Alexander Hoischen from Radboud
UMC, will share their latest research on OGM for RUGD.
Three genomics researchers will participate in separate featured
scientific presentations, highlighting use of OGM in genetic
disorder testing. Dr. Claudia Carvalho of the Pacific Northwest
Research Institute will present on complex genomic rearrangement
structures (CGRs) in neurodevelopmental disorders. Dr.
Laïla El Khattabi will present on a recent study highlighting
the OGM in the characterization of complex SVs. Dr. Kornelia
Neveling from Radboud UMC will present on repeat expansion disorder
testing using OGM.
Scientific presentations and poster sessions from Bionano and
customers include:
Room |
Title |
Presenter |
Presented |
ACV, Room G, Level-2 |
See More, Know More: How OGM Provides Answers for Rare Undiagnosed
Genetic Disease |
Trost D., Hoischen A., Delpu Y. |
June 11, 202210:00-11:30 CEST |
Hall E-2, Concurrent Symposia S05 |
S05.2: Identification of Complex Genomic Rearrangement Structures
in Disease |
Carvalho C. |
June 12, 20228:30-10:00 CEST |
Hall E2-Workshop: What’s New in Cytogenomics? |
W12: Optical Genome Mapping Enables Next-Generation
Cytogenetics |
El Khattabi L. |
June 13, 202214:00-15:30 CEST |
Hall E2- Concurrent Sessions C27 |
C27.3: Optical Genome Mapping for Repeat Expansion Disorder
Testing |
Neveling K. |
June 14, 202211:00-12:30 CEST |
Poster |
Title |
Author |
Presented |
P15.004.A |
Structural and copy number variant detection, filtering,
annotation, and classification by optical genome mapping in
constitutional disorders |
Delpu Y. |
Poster Session June 12, 202213:00-14:00 CEST |
P11.010.A |
FSHD analysis pipeline by Bionano optical genome mapping: A field
report |
Heinrich U. |
Poster Session June 12, 202213:00-14:00 CEST |
P13.107.A |
An insertion in the MSH2 gene detected by Bionano optical mapping
and confirmed by Nanopore sequencing in a family with suspected
Lynch Syndrome |
Aaløkken R. |
Poster Session June 12, 202213:00-14:00 CEST |
P09.027.C |
Optical genome mapping analysis of FMR1 expansions in fragile X
syndrome and multi-site validation |
Venier A. |
Poster Session June 13, 202212:45-13:45 CEST |
P15.003.D |
Comparative benchmarking of optical genome mapping and chromosomal
microarray reveals high technological concordance in CNV
identification and structural variant refinement |
Jaber D. |
Poster Session June 13, 202215:45-16:45 CEST |
P16.020.D |
Optical genome mapping in routine human genetic diagnostics:
Lessons learned |
Dremsek P. |
Poster Session June 13, 202215:45-16:45 CEST |
P16.032.D |
Optical Genome Mapping as a diagnostic tool in cases of unresolved
rare diseases |
Trost D. |
Poster Session June 13, 202215:45-16:45 CEST |
EP15.018 |
A paracentric inversion that disrupts the SHANK2 gene resolved
using cytogenomics |
Huyghebaert J. |
E-Poster |
EP15.002 |
Recurrent constitutional chromosome five inversion revisited |
Doco-Fenzy M. |
E-Poster |
More details on the conference can be found here.
“We are thrilled to see the broad range of presentations
featuring OGM at ESHG this year. These institutions and their
research teams have conducted innovative research to help
demonstrate the potential utility of OGM as a more sensitive,
faster and less expensive alternative to traditional cytogenetics
methods,” commented Erik Holmlin, president and chief executive
officer of Bionano. “We are also excited for attendees to learn
more about our collaboration with Hamilton and the Long String
VANTAGE automation system. We believe this innovation can
significantly reduce time to results, reduce hands on time and
improve OGM performance by standardizing the process of UHMW DNA
isolation, and we look forward to sharing more at ESHG.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome
through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which
integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “potential,” “can,” “will,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the potential contribution of our OGM solutions
to offer the anticipated benefits for and contributions to the
areas reported in the presentations given and posters made
available at the ESHG Annual Meeting; anticipated benefits and
improvements resulting from the use of Long String VANTAGE to
reliably and consistently isolate high quality and sufficient
quantity of UHMW DNA for use with OGM . Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; the ability
of our OGM solutions to offer the anticipated benefits for and
contributions to the areas of research reported in the
presentations given and posters made available at the ESHG Annual
Meeting; future study results contradicting the results reported in
the presentations given and posters made available at the ESHG
Annual Meeting; the ability of Long String VANTAGE system to
reliably and consistently isolate high quality and sufficient
quantity of UHMW DNA for use with OGM; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024